---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089301"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:45:55.709759+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance

## Summary
- Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).
- Net loss $46.2M vs $47.8M YoY; Adjusted EBITDA loss $21.4M vs $24.8M.
- clonoSEQ test volume 18,520 (+36% YoY); recognized $3.0M MRD regulatory milestone.
- FY 2024 MRD revenue guidance raised to $140-145M (from $135-140M); total OPEX guidance lowered to $340-350M.
- Cash and securities $291.9M as of June 30.

## SEC filing metadata
- accession: 0000950170-24-089301
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017024089301/0000950170-24-089301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017024089301/adpt-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089301
- JSON: https://secwatch.observer/filing/0000950170-24-089301.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089301.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.